A series of benzylamine derivative (BAD) supported platinum(IV) complexes (PtCl4(BADs)2) have been synthesized. The complexes were tested in vitro against the MCF-7 cell line, and the 4-fluoro and 4-chloro containing complexes expressed impressive anticancer activities. Their DNA binding nature for a structureâactivity relationship (SAR) study was investigated with physicochemical-indicators (PCI) which categorized them as good intercalators for hostâguest chemistry. A mechanism for drug efficacy is proposed by analysis of the resultant viscosity and surface tension of PtCl4(BADs)2âDNA solutions named as the drug-friccohesity interaction (DFI). The complexes have shown significant antioxidant activity, determined on the basis of free radical scavenging effects due to their terminating action against the reactive species.
我们合成了一系列
苄胺衍
生物(BAD)支持的
铂(IV)配合物(PtCl4(BADs)2)。这些配合物针对 MCF-7
细胞系进行了体外测试,其中含有 4-
氟和 4-
氯配合物的抗癌活性令人印象深刻。研究人员利用理化指标(PCI)对这些复合物的 DNA 结合特性进行了研究,并将其归类为良好的主客体
化学中间体,以进行结构与活性关系(
SAR)研究。通过分析 PtCl4(BADs)2âDNA 溶液产生的粘度和表面张力,提出了一种药物功效机制,即药物-粘度相互作用(DFI)。这些复合物具有显著的抗氧化活性,这是根据其对活性物种的终止作用所产生的自由基清除效果确定的。